Trials / Enrolling By Invitation
Enrolling By InvitationNCT06700681
RCT Comparing Remimazolam With Propofol Under EEG DSA Guidance During Cardiac Electrophysiology Studies and Ablation
Safety and Efficacy of Remimazolam Compared With Propofol Under EEG DSA Guiding During Cardiac Electrophysiology Studies and Ablation: Randomized Controlled Trial
- Status
- Enrolling By Invitation
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Taipei Veterans General Hospital, Taiwan · Other Government
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Brief Summary: The goal of this RCT is to compare the Safety and efficacy of remimazolam compared with propofol under EEG DSA guiding during cardiac electrophysiology studies and ablation. The main questions it aims to answer are: * Is Remimazolam as efficacy as propofol in cardiac electrophysiology studies and ablation? * Is Remimazolam lower hypotension episodes or lower vasopressor dosages compare with propofol in cardiac electrophysiology studies and ablation? If there is a comparison group: Researchers will compare \[arm information\] to see if \[insert effects\]. Researchers will compare Remimazolam to Propofol to see if Remimazolam is more feasible in cardiac electrophysiology studies and ablation. Participants will receive either Remimazolam or Propofol sedation during study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propofol | TIVA induction and maintain with Propofol. |
| DRUG | Remimazolam | TIVA induction and maintain with Remimazolam. |
| DEVICE | With intubation and controlled ventilation to maintain airway | Patient receives intubation and controlled ventilation to maintain airway. |
| DEVICE | Maintain spontaneous ventilation without intubation | Patient maintains spontaneous ventilation without intubation. |
Timeline
- Start date
- 2024-09-20
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-11-22
- Last updated
- 2024-11-22
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06700681. Inclusion in this directory is not an endorsement.